Comprehensive Stock Comparison
Compare Cogent Biosciences, Inc. (COGT) vs BridgeBio Pharma, Inc. (BBIO) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Stability / Safety | BBIO | Beta 1.04 vs COGT's 1.43 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | COGT | +415.9% vs BBIO's +90.5% |
| Efficiency (ROA) | COGT | -35.1% ROA vs BBIO's -77.9% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Cogent Biosciences is a biotechnology company developing precision therapies for genetically defined diseases, particularly focusing on cancers driven by specific mutations. The company generates revenue primarily through research collaborations and licensing agreements — it currently has no commercial products and relies on funding from partnerships and equity offerings to advance its clinical pipeline. Its key competitive advantage lies in its targeted approach to inhibiting specific oncogenic mutations like KIT D816V, which could offer differentiated efficacy and safety profiles compared to broader kinase inhibitors.
BridgeBio Pharma is a biopharmaceutical company focused on discovering and developing precision medicines for genetic diseases. It generates revenue primarily through drug development partnerships and potential future product sales — though currently in pre-revenue stage with multiple programs in clinical trials. The company's key advantage is its efficient hub-and-spoke operating model that allows rapid development of targeted therapies for rare genetic conditions.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
BBIO leads in 2 of 6 categories — strongest in Financial Metrics and Valuation Metrics. 3 categories are tied.
Financial Metrics (TTM)
BBIO and COGT operate at a comparable scale, with $502M and $0 in trailing revenue.
| Metric | COGTCogent Bioscience… | BBIOBridgeBio Pharma,… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $502M |
| EBITDAEarnings before interest/tax | -$333M | -$560M |
| Net IncomeAfter-tax profit | -$329M | -$729M |
| Free Cash FlowCash after capex | -$266M | -$458M |
| Gross MarginGross profit ÷ Revenue | — | +94.4% |
| Operating MarginEBIT ÷ Revenue | — | -113.3% |
| Net MarginNet income ÷ Revenue | — | -145.3% |
| FCF MarginFCF ÷ Revenue | — | -91.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +25.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -13.1% | +28.6% |
Valuation Metrics
| Metric | COGTCogent Bioscience… | BBIOBridgeBio Pharma,… |
|---|---|---|
| Market CapShares × price | $6.3B | $12.9B |
| Enterprise ValueMkt cap + debt − cash | $6.2B | $12.4B |
| Trailing P/EPrice ÷ TTM EPS | -15.24x | -17.54x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 25.79x |
| Price / BookPrice ÷ Book value/share | 4.13x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), COGT scores 4/9 vs BBIO's 3/9, reflecting mixed financial health.
| Metric | COGTCogent Bioscience… | BBIOBridgeBio Pharma,… |
|---|---|---|
| ROE (TTM)Return on equity | -51.7% | — |
| ROA (TTM)Return on assets | -35.1% | -77.9% |
| ROICReturn on invested capital | -66.4% | — |
| ROCEReturn on capital employed | -58.2% | -80.6% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 3 |
| Debt / EquityFinancial leverage | 0.40x | — |
| Net DebtTotal debt minus cash | -$59M | -$560M |
| Cash & Equiv.Liquid assets | $312M | $570M |
| Total DebtShort + long-term debt | $253M | $10M |
| Interest CoverageEBIT ÷ Interest expense | -108.87x | -6.10x |
Total Returns (with DRIP)
A $10,000 investment in COGT five years ago would be worth $47,205 today (with dividends reinvested), compared to $9,245 for BBIO. Over the past 12 months, COGT leads with a +415.9% total return vs BBIO's +90.5%. The 3-year compound annual growth rate (CAGR) favors BBIO at 79.9% vs COGT's 43.2% — a key indicator of consistent wealth creation.
| Metric | COGTCogent Bioscience… | BBIOBridgeBio Pharma,… |
|---|---|---|
| YTD ReturnYear-to-date | +11.8% | -15.0% |
| 1-Year ReturnPast 12 months | +415.9% | +90.5% |
| 3-Year ReturnCumulative with dividends | +193.7% | +482.1% |
| 5-Year ReturnCumulative with dividends | +372.1% | -7.6% |
| 10-Year ReturnCumulative with dividends | -12.6% | +141.3% |
| CAGR (3Y)Annualised 3-year return | +43.2% | +79.9% |
Risk & Volatility
BBIO is the less volatile stock with a 1.04 beta — it tends to amplify market swings less than COGT's 1.43 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. COGT currently trades 88.8% from its 52-week high vs BBIO's 78.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | COGTCogent Bioscience… | BBIOBridgeBio Pharma,… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.43x | 1.04x |
| 52-Week HighHighest price in past year | $43.73 | $84.94 |
| 52-Week LowLowest price in past year | $3.72 | $28.33 |
| % of 52W HighCurrent price vs 52-week peak | +88.8% | +78.3% |
| RSI (14)Momentum oscillator 0–100 | 58.0 | 39.0 |
| Avg Volume (50D)Average daily shares traded | 1.7M | 2.5M |
Analyst Outlook
Wall Street rates COGT as "Buy" and BBIO as "Buy". Consensus price targets imply 48.8% upside for BBIO (target: $99) vs 23.9% for COGT (target: $48).
| Metric | COGTCogent Bioscience… | BBIOBridgeBio Pharma,… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $48.13 | $98.92 |
| # AnalystsCovering analysts | 12 | 26 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.4% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Cogent Biosciences,… (COGT) | 100 | 1,725.45 | +1625.5% |
| BridgeBio Pharma, I… (BBIO) | 100 | 242.91 | +142.9% |
Cogent Biosciences,… (COGT) returned +372% over 5 years vs BridgeBio Pharma, I… (BBIO)'s -8%. A $10,000 investment in COGT 5 years ago would be worth $47,205 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Cogent Biosciences,… (COGT) | $6M | $0.00 | -100.0% |
| BridgeBio Pharma, I… (BBIO) | $0.00 | $502M | — |
Cogent Biosciences, Inc.'s revenue grew from $6M (2016) to $0M (2025) — a -100.0% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Cogent Biosciences,… (COGT) | -2.9% | -9.5% | -233.3% |
| BridgeBio Pharma, I… (BBIO) | -6.4% | -145.3% | -2162.2% |
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Cogent Biosciences,… (COGT) | -2.45 | -2.55 | -4.1% |
| BridgeBio Pharma, I… (BBIO) | -0.33 | -3.79 | -1048.5% |
Cogent Biosciences, Inc.'s EPS grew from $-2.45 (2016) to $-2.55 (2025).
Chart 5Free Cash Flow — 5 Years
Cogent Biosciences, Inc. generated $-266M FCF in 2025 (-340% vs 2021). BridgeBio Pharma, Inc. generated $-447M FCF in 2025 (+18% vs 2021).
COGT vs BBIO: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is COGT or BBIO a better buy right now?
Analysts rate Cogent Biosciences, Inc. (COGT) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — COGT or BBIO?
Over the past 5 years, Cogent Biosciences, Inc. (COGT) delivered a total return of +372.1%, compared to -7.6% for BridgeBio Pharma, Inc. (BBIO). A $10,000 investment in COGT five years ago would be worth approximately $47K today (assuming dividends reinvested). Over 10 years, the gap is even starker: BBIO returned +141.3% versus COGT's -12.6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — COGT or BBIO?
By beta (market sensitivity over 5 years), BridgeBio Pharma, Inc. (BBIO) is the lower-risk stock at 1.04β versus Cogent Biosciences, Inc.'s 1.43β — meaning COGT is approximately 38% more volatile than BBIO relative to the S&P 500.
04Which has better profit margins — COGT or BBIO?
Cogent Biosciences, Inc. (COGT) is the more profitable company, earning 0.0% net margin versus -145.3% for BridgeBio Pharma, Inc. — meaning it keeps 0.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: COGT leads at 0.0% versus -113.3% for BBIO. At the gross margin level — before operating expenses — BBIO leads at 94.4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — COGT or BBIO?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is COGT or BBIO better for a retirement portfolio?
For long-horizon retirement investors, BridgeBio Pharma, Inc. (BBIO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.04), +141.3% 10Y return). Both have compounded well over 10 years (BBIO: +141.3%, COGT: -12.6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between COGT and BBIO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.